Enbrel All Financial Data in US $ (mln)

Word Search (Top 10 - by date)

Novartis Presents New Data Showing That the Majority of Patients are Able to Maintain Clear Or Almost Clear Skin with Cosentyx Across 3 Years
Novartis (October 10, 2015)
FDA Accepts Sandoz Regulatory Submission for a Proposed Biosimilar Etanercept
Novartis (October 02, 2015)
Merck and Samsung Bioepis Announce Approval of BRENZYS™ (Etanercept), a Biosimilar of Enbrel, in Korea
Merck & Co (September 08, 2015)
Rheumatologists Report Widespread Adoption And Anticipated Gains For Celgene's Otezla In Psoriatic Arthritis (PsA) (September 08, 2015)
Chiasma Expands Management Team with Announcement of Anand Varadan as Chief Commercial Officer
Chiasma (August 10, 2015)
Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57
Amgen (July 30, 2015)
Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints
Merck & Co (June 10, 2015)
Pfizer Announces 12 Presentations Including New Research Data on Tofacitinib for Chronic Plaque Psoriasis and Atopic Dermatitis at World Congress of Dermatology
Pfizer (June 08, 2015)
Neurocrine Biosciences, Inc. Announces Appointment of Eric Benevich as Chief Commercial Officer
Neurocrine Biosciences (June 02, 2015)
Amgen's First Quarter 2015 Revenues Increased 11 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 33 Percent To $2.48
Amgen (April 21, 2015)

Displaying 10 out of a possible 681 unique stories.
Results Sorted By date

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status (expiry date/ number), deals (upfront/ milestones), license revenues (royalties/ co-promotion) and much more.

Product Name Information

Product: Enbrel
Generic Name:   etanercept
Therapeutic Subcategory:     Other anti-rheumatics
Therapeutic Subcategory:     Anti-virals

Product Sales Summary 2012/13

Annual Sales WW - Sales Growth per Year (%)
Rank1 Generic Name Therapeutic Subcategory 2012 2013 2013
Enbrel2 8,496 8,778 +3%
Note: Shaded Cells3

Clinical Trial Coverage: No. of Trials involving Product

Trial Count
Enbrel4 426


Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate


EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.

Register to access more FREE content:

  • 2011 Product Sales analysis
  • Download analysis into Excel
  • Search 2 yrs of company press releases

Research Codes Synonyms

Product: Enbrel

Register for Free Analysis

Register to access more free insights and analysis from Evaluate.

Register Now